705 results on '"Beresford, Michael W."'
Search Results
2. Type I interferon associated epistasis may contribute to early disease-onset and high disease activity in juvenile-onset lupus
3. Reporting involvement activities with children and young people in paediatric research: a framework analysis
4. Urinary complement proteins are increased in children with IgA vasculitis (Henoch-Schönlein purpura) nephritis
5. P2RX7 gene variants associate with altered inflammasome assembly and reduced pyroptosis in chronic nonbacterial osteomyelitis (CNO)
6. Towards stratified treatment of JIA: machine learning identifies subtypes in response to methotrexate from four UK cohorts
7. Real world treatment of juvenile-onset systemic lupus erythematosus: Data from the UK JSLE cohort study
8. Longitudinal analysis of urinary proteins in lupus nephritis – A pilot study
9. P093 What’s in a name? Misnaming and renaming of Juvenile Idiopathic Arthritis has long-term impacts
10. P089 Comprehensive comparison of current guidelines in the management of Systemic Lupus Erythematosus in children, with a focus on Lupus Nephritis
11. Towards stratified treatment of JIA: machine learning identifies subtypes in response to methotrexate from four UK cohorts
12. Serum protein signatures differentiate paediatric autoimmune/inflammatory disorders
13. Kidney outcomes for children with lupus nephritis
14. Patient-reported wellbeing and clinical disease measures over time captured by multivariate trajectories of disease activity in individuals with juvenile idiopathic arthritis in the UK: a multicentre prospective longitudinal study
15. Chronic Nonbacterial Osteomyelitis
16. Frequency of biologic switching and the outcomes of switching in children and young people with juvenile idiopathic arthritis: a national cohort study
17. Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial
18. Contribution of rare and predicted pathogenic gene variants to childhood-onset lupus: a large, genetic panel analysis of British and French cohorts
19. Mesenchymal Stem Cells in the Pathogenesis and Therapy of Autoimmune and Autoinflammatory Diseases
20. Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches
21. The prevention and treatment of glucocorticoid-induced osteopaenia in juvenile rheumatic disease: A randomised double-blind controlled trial
22. Ophthalmology research in the UK’s National Health Service: the structure and performance of the NIHR’s Ophthalmology research portfolio
23. Urinary biomarkers in childhood lupus nephritis
24. Establishing an international awareness day for paediatric rheumatic diseases: reflections from the inaugural World Young Rheumatic Diseases (WORD) Day 2019
25. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy
26. Mesangial cells are key contributors to the fibrotic damage seen in the lupus nephritis glomerulus
27. Anti-neutrophil cytoplasmic antibodies and their clinical significance
28. OA39 Development of a Childhood Lupus Low Disease Activity State definition: recommendations from the International Childhood Lupus Treat-to-Target Task Force
29. Juvenile-onset systemic lupus erythematosus: how to diagnose and manage
30. The human glomerular endothelial cells are potent pro-inflammatory contributors in an in vitro model of lupus nephritis
31. Stuck in transit: A qualitative study of the transitional care needs of young people with epilepsy and juvenile idiopathic arthritis.
32. Management and treatment of children, young people and adults with systemic lupus erythematosus: British Society for Rheumatology guideline scope.
33. 22. Genome-Wide Association Study of Methotrexate non-response in Juvenile Idiopathic Arthritis
34. 20. British Paediatric Surveillance Unit (BPSU) study of Behçet’s syndrome in children and young people in the United Kingdom
35. 16. Clinical Factors Associated with Non-Response to Methotrexate in Children with Juvenile Idiopathic Arthritis: Results from the Childhood Arthritis Response to Treatment Consortium
36. 6. Developing a UK/ROI study of the incidence of JSLE in children and young people and their access to care: a collaborative approach
37. Protective parents and permissive children: what qualitative interviews with parents and children can tell us about the feasibility of juvenile idiopathic arthritis trials
38. Oral Ulcers in Juvenile-Onset Systemic Lupus Erythematosus: A Review of the Literature
39. Urinary complement proteins are increased in children with IgA vasculitis (Henoch-Schönlein purpura) nephritis
40. Pulmonary hypertension in juvenile-onset systemic lupus erythematosus: a case series
41. P66 Adalimumab originator versus biosimilar in children and young people with JIA
42. Successful stopping of biologic therapy for remission in children and young people with juvenile idiopathic arthritis
43. Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research
44. European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative
45. European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative
46. Successful stopping of biologic therapy for remission in children and young people with juvenile idiopathic arthritis.
47. A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial)
48. Clinical predictors of proteinuric remission following an LN flare - evidence from the UK JSLE cohort study
49. Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus
50. Panel sequencing links rare, likely damaging gene variants with distinct clinical phenotypes and outcomes in juvenile-onset SLE
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.